Sandu Pharmaceuticals Ltd manufactures and trades Ayurvedic proprietary medicines.Product Portfolio: Company manufactures over 100 types of products, including oils, syrups, granules, powder, and avlehas, which are marketed under the Sandu brand viz, Sandu Ashoka Compound, Sandu Abhayarishta, Sandu Arvindasav, Sandu Balant Kadha No. 1, Sandu Debix Tablet, Sandu Bhunimbadi Kadha,...
Sandu Pharmaceuticals has opened a special window from February 5, 2026, to February 4, 2027, for shareholders to re-lodge transfer requests for physical share certificates. This initiative, following SEBI guidelines, is specifically for requests made before April 1, 2019, that were previously rejected or not processed due to documentation issues....
Sandu Pharmaceuticals has announced its 41st Annual General Meeting (AGM) will be held virtually via video conference. Shareholders can participate and vote on all resolutions using a remote e-voting system, with an additional option for e-voting during the meeting. The Annual Report for the financial year 2025-26 and the AGM...
Sandu Pharmaceuticals announced its 41st Annual General Meeting will convene virtually on September 11, 2026. The company is making the Annual Report for FY 2025-26 available electronically and through a web-link for shareholders without registered emails. Shareholders are encouraged to update their email and KYC details, including PAN and bank...
Sandu Pharmaceuticals has scheduled its 41st Annual General Meeting for September 11, 2026, at 4:30 PM IST, to be held via video conference. The Board earlier **put forward** a dividend of Re 1.00 per equity share for the financial year ending March 31, 2026. This dividend requires shareholder approval at...
Sandu Pharmaceuticals' board has approved the financial results for the quarter ended June 30, 2026, reporting a profit of 0.23 Cr on revenue from operations of 16.39 Cr. The board also approved the Annual Report and related documents for the financial year ended March 31, 2026. A record date for...
